Section Arrow
CELC.NASDAQ
- Celcuity
Quotes are at least 15-min delayed:2025/06/01 08:10 EDT
Last
 10.63
-0.19 (-1.76%)
Day High 
10.825 
Prev. Close
10.82 
1-M High
11.43 
Volume 
118.68K 
Bid
10.3
Ask
12
Day Low
10.5 
Open
10.74 
1-M Low
9.51 
Market Cap 
409.71M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 10.61 
20-SMA 10.6 
50-SMA 10.29 
52-W High 19.77 
52-W Low 7.575 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.05/-4.11
Enterprise Value
507.50M
Balance Sheet
Book Value Per Share
2.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/06/01 08:10 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic propertiesare differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.